GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Issuance of Stock

Cabio Biotech (Wuhan) Co (SHSE:688089) Issuance of Stock : ¥0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Issuance of Stock?

Cabio Biotech (Wuhan) Co's Issuance of Stock for the three months ended in Dec. 2024 was ¥0.0 Mil.

Cabio Biotech (Wuhan) Co's Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was ¥0.0 Mil.


Cabio Biotech (Wuhan) Co Issuance of Stock Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co Issuance of Stock Chart

Cabio Biotech (Wuhan) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cabio Biotech (Wuhan) Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cabio Biotech (Wuhan) Co Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cabio Biotech (Wuhan) Co Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Cabio Biotech (Wuhan) Co Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430075
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Shang Yun Core technical personnel
Xiao Min senior management
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director

Cabio Biotech (Wuhan) Co Headlines

No Headlines